Dyskinesias in humans are prevented by administering a therapeutically effective dose of a NR1A/2B site-selective NMDA receptor antagonist compound to a human.
Method for preventing dyskinesias with selective NMDA-Antagonists
申请人:WARNER-LAMBERT COMPANY
公开号:EP1254661A1
公开(公告)日:2002-11-06
Dyskinesias in humans are prevented by administering a therapeutically effective dose of a NR1A/2B site-selective NMDA receptor antagonist compound to a human.